How can we achieve universal access to low-cost treatment for HIV?

• Main Authors: Andrew M. Hill (Author), Anton L. Pozniak (Author)
• Formato: Libro
• Publicado: Elsevier, 2016-10-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Mass production of low-cost antiretrovirals (ARVs) has already allowed over 17 million individuals to access treatment for HIV infection, mainly in low-income countries. It is possible to manufacture combination ARVs for $110 per person-year, using tenofovir (TDF), lamivudine (3TC) and efavirenz (EF...